close

SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. The company's products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma. The company was founded in 1989 and is headquartered in Foster City, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	6.34
Volume	(mio) 3.66
Volume Avg	191273
52 Week High	6.88
52 Week Low	3.30
PE	14.52
PE (group average)	39
EPS Year	0.36
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-11.11%
EPS change Q/Q next Q est	14.29%
EPS change Y/Y	-22.73%
REV change Q/Q	-8.05%
REV change Q/Q Yr ago	20.56%
EPS next Q est	0.07
EPS next Y est	0.56
Divident Annual	0.00
Dividend Yield	0%